REVIEW ARTICLE

Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines

Bassem Yamout[1] · Riadh Gouider[2] · Raed Al-Roughani[3] · Salman Aljarallah[4] · Nevine Shalaby[5] · Jaber Al-Khabouri[6] ·
Anu Jacob[7] · Jihad Inshasi[8,9] · Akram Mahdawi[10] · Ahmed Shatila[11] · Maya Zeineddine[12] · Sarmad Al-Mashetah[10] ·
Beatrice Canibano[13,14] · Saeed Bohlega[15] · Fatema Abdulla[16] · Ilham Slassi[17] · Aly Hassan[18] · Sandra Ahmed[19] ·
Magd Zakaria[20] · Mohammed AlJumah[21] · Yaser Al-Malik[22,23,24]

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune disorder affecting the central nervous system, often misdiagnosed as multiple sclerosis. The identification of aquaporin-4–IgG (AQP4-IgG) has improved diagnostic precision and enabled targeted therapies. Given the unique regional challenges in healthcare delivery across the Middle East and North Africa (MENA) region, the Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) convened an expert panel to develop evidence-based, region-specific consensus recommendations for diagnosis and management. These guidelines endorse the 2015 International Panel for NMO Diagnosis (IPND) criteria, emphasizing AQP4-IgG testing via cell-based assays. Differential diagnosis should consider multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and acute disseminated encephalomyelitis (ADEM). For acute treatment: initiate high-dose intravenous methylprednisolone promptly and use plasma exchange early for severe or steroid-refractory attacks. For long-term immunotherapy, monoclonal antibodies (rituximab, inebilizumab, eculizumab, ravulizumab, satralizumab, or tocilizumab) are recommended according to availability and patient factors; conventional immunosuppressants remain alternatives when biologics are inaccessible. Guidance is provided for pediatric patients and for pregnancy and breastfeeding, including planning after ≥ 12 months of disease stability and early postpartum treatment resumption. These MENACTRIMS guidelines aim to improve NMOSD outcomes across the region by promoting accurate diagnosis and timely, effective therapy.

1 Introduction

Neuromyelitis optica spectrum disorder (NMOSD) is a severe, relapsing, inflammatory disorder of the central nervous system (CNS) that predominantly targets the optic nerves and spinal cord [1]. The clinical presentation can be diverse and the condition is often misdiagnosed as multiple sclerosis (MS) [2] or other neurological disorders [3]. The discovery in 2004 of a highly specific biomarker of the disease, the AQP4-IgG that binds to water channels at the astrocytic end-feet, redefined the disease and allowed for a more accurate diagnosis. Recently, four monoclonal antibodies have been evaluated in large randomized controlled trials, leading to their approval by regulatory agencies in the USA, Europe, and other countries for the treatment of NMOSD.

> **Key Points**
>
> This guideline provides region-specific recommendations to help doctors in the Middle East and North Africa diagnose and treat neuromyelitis optica spectrum disorder (NMOSD), a serious autoimmune disease often confused with multiple sclerosis.
>
> It highlights the importance of accurate antibody testing, early treatment of relapses, and use of approved therapies such as monoclonal antibodies.
>
> The guidelines also address special cases such as children and pregnant women to improve patient outcomes across the region.

Extended author information available on the last page of the article

The Middle East and North Africa (MENA) region faces unique challenges in the diagnosis and management of NMOSD owing to variations in healthcare infrastructure, availability of specialized care, and regional differences in disease presentation. The aim of this consensus is to provide comprehensive, region-specific guidelines for the diagnosis and management of NMOSD, focusing on AQP4-IgG-positive and seronegative NMOSD and does not cover myelin oligodendrocyte glycoprotein (MOG)-associated disease (MOGAD), with the goal of improving patient outcomes through early diagnosis, appropriate differential diagnosis, effective treatment strategies, and adherence to international standards adapted to the regional context.

2 Consensus Methodology

The Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis (MENAC-TRIMS) invited a group of neurologists from different countries in the MENA region with experience in managing NMOSD to a workshop in Dubai, UAE, in June 2024. The panel consisted of academic, hospital-based, and community general neurologists with expertise in NMOSD to ensure a wide diversity of opinions. Panelists were selected on the basis of predefined criteria, including extensive clinical experience in NMOSD, management of a significant number of patients with the disease in their respective centers, recognized expertise within the MENA region, and academic contributions to the field (research publications, teaching, and guideline development). Additional considerations included geographic representation to ensure regional applicability of the recommendations. The guidelines were divided into six sections: diagnostic criteria and differential diagnosis, current therapies, relapse treatment, pregnancy and breastfeeding, pediatric NMOSD, and treatment recommendations by serostatus. After a plenary discussion, each section was assigned to a panel member to review and prepare final recommendations on the basis of the most recent scientific evidence. The panel reconvened in January 2025 in Dubai, UAE, discussed all recommendations and after extensive deliberation agreed on all points with minimal disagreement or concerns. The final recommendations were based on expert consensus and literature review. A recommendation was approved if at least 80% agreement was achieved by open voting. Recommendations not reaching this threshold were revised and re-voted until consensus was achieved.

3 Diagnosis

Accurate diagnosis is critical for proper treatment and improved patient outcomes. The International Panel for Neuromyelitis Optica (NMO) Diagnosis (IPND) published revised criteria in 2015 to enhance diagnostic accuracy by incorporating serological, magnetic resonance imaging (MRI), and clinical characteristics [4]. A revision of the current criteria is expected to be published by the end of 2025.

3.1 Diagnostic Criteria

The IPND 2015 criteria categorize NMOSD into AQP4-IgG positive and AQP4-IgG negative/unknown (Table 1). The presence of AQP4-IgG is central to the diagnosis in many patients, but the criteria also recognize the need to diagnose NMOSD in the absence of these antibodies on the basis of clinical and radiological features.

For patients who test positive for AQP4-IgG antibodies, a diagnosis of NMOSD requires at least one core clinical characteristic and exclusion of alternative diagnoses.

In patients who are AQP4-IgG negative or whose antibody status is unknown, the diagnosis of NMOSD requires:

- At least two core clinical characteristics meeting all of the following criteria:

  o At least one core clinical characteristic must be optic neuritis, acute myelitis with longitudinally extensive transverse myelitis (LETM), or area postrema syndrome (APS).
  o Dissemination in space, which means two or more different core clinical characteristics.
  o Fulfillment of additional MRI requirements as applicable.

- Exclusion of alternative diagnoses.

At the time of publication of the 2015 criteria, approximately 30% of patients with NMOSD tested negative for AQP4-IgG [4]. Subsequently, a proportion (up to 40%) of AQP4-IgG-negative NMOSD were found to be myelin oligodendrocyte glycoprotein IgG (MOG-IgG) [5] positive and can now be classified as MOGAD [6]. Specific criteria for the diagnosis of MOGAD are now available combining clinical features and serological testing [7]. Patients with neither antibody are called double-seronegative NMOSD (dsNMOSD). It is increasingly evident that dsNMOSD is a syndrome with heterogeneous etiologies and might include not only inflammatory but genetic, metabolic, and other

Table 1 NMOSD criteria in current use

2015 International Panel for NMO Diagnosis (IPND) criteria*	
Diagnostic criteria for anti-AQP4(+) NMOSD	Diagnostic criteria for NMOSD without AQP4-IgG and NMOSD with unknown AQP4-IgG status
1. At least 1 core clinical characteristic	1. At least 2 core clinical characteristics a. At least 1 core clinical characteristic must be ON, acute myelitis with LETM, or APS b. Dissemination in space ($\geq$ 2 different core clinical characteristics) c. Fulfillment of additional MRI requirements, as applicable
2. Positive test for AQP4-IgG	2. Negative test for AQP4-IgG using best available method[a]
3. Exclusion of alternative diagnoses	3. Exclusion of alternative diagnoses
Core clinical characteristics	Additional MRI requirements for NMOSD without AQP4-IgG and NMOSD with unknown AQP4-IgG status
1. ON	1. Acute ON: requires brain MRI showing a) normal findings or only nonspecific white matter lesions, or b) optic nerve MRI with T2 or gad(+) lesion extending over >1/2 optic nerve length or involving the optic chiasm
2. Acute myelitis	2. Acute myelitis: requires associated intramedullary MRI lesion extending over $\geq$ 3 contiguous segments (LETM) or $\geq$ 3 contiguous segments of spinal cord atrophy
3. APS: episode of otherwise unexplained hiccups or nausea and vomiting	3. APS: requires associated dorsal medulla/area postrema lesions
4. Acute brainstem syndrome	4. Acute brainstem syndrome: requires associated periependymal brainstem lesions
5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions	
6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions	

AQP4 Aquaporin-4, *APS* Area Postrema Syndrome, *IgG* Immunoglobulin G, *Gad(+)* Gadolinium-enhancing, *LETM* Longitudinally extensive transverse myelitis, *MRI* Magnetic resonance imaging, *NMO* Neuromyelitis optica, *NMOSD* Neuromyelitis optica spectrum disorder, *ON* optic neuritis, C*BA* Cell-based assays

*Reproduced from: Wingerchuk DM et al. Neurology 2015; 85:177–89 with permission from Wolters Kluwer Health, Inc. License Number: 5996501422647

[a]Or testing unavailable.

causes. Accordingly, careful diagnostic work-up is essential before confirming diagnosis [8].

Cell-based assays (CBAs) are strongly recommended in the IPND 2015 diagnostic criteria for testing for AQP4-IgG [4]. CBAs offer higher sensitivity (76.7%) and specificity (up to 100% in some studies) compared with enzyme-linked immunosorbent assays [9] (47% and 85%, respectively). Different CBAs provide different sensitivities, with fixed CBAs showing slightly lower sensitivity compared with live CBAs [10]. CBAs are widely available in the MENA region. We recommend using either live or fixed CBAs, rather than ELISA, in testing for AQP4-IgG. AQP4-IgG should be ideally tested during a relapse before any immunotherapy, including corticosteroids, is initiated. CSF testing is not reliable [11].

3.2 Red Flags in Diagnosing NMOSD/ Differential Diagnosis

Accurate differential diagnosis is essential to distinguish NMOSD from other neurological disorders that have overlapping symptoms but require different treatment approaches. Key differential diagnoses include MS, MOGAD, and acute disseminated encephalomyelitis (ADEM), although other entities should be considered such as vasculitis, CNS infections, and malignancies [11]. LETM, a core clinical presentation of NMOSD, can be seen with other disorders including autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy, neurosarcoidosis, Sjögren syndrome, systemic lupus erythematosus, Behçet disease, paraneoplastic myelitis, post-infectious myelitis, acute spinal cord infarction, and dural arteriovenous fistula [12]. It is of note that 14% of patients with NMOSD presenting with

myelitis exhibit a short segment lesion on MRI [13]. APS, another core clinical presentation of NMOSD is seen in 9–14% of patients, and presents with nausea, vomiting, and hiccups. It is frequently misdiagnosed initially as a gastro-enterological disorder [14]. The comparative clinical, imaging, and laboratory features of NMOSD, MS, MOGAD, and ADEM are summarized in Table 2.

3.2.1 Multiple Sclerosis

MS is the most common differential diagnosis of NMOSD owing to their overlapping clinical presentations, including optic neuritis and transverse myelitis. The newly published 2024 McDonald criteria will assist in distinguishing between the two diseases more effectively, particularly through the use of highly specific MRI biomarkers, including the central vein sign and paramagnetic rim lesions [15]. However, there are several distinguishing features:

- MRI characteristics: MS and NMOSD can be differentiated on the basis of distinct MRI findings. MS typically presents with multifocal brain lesions, often located in periventricular, juxtacortical, and infratentorial regions [16]. Specific brain MRI characteristics that suggest MS include lesions in the inferior temporal lobe adjacent to the lateral ventricle, cortical/juxtacortical lesions, and Dawson's finger-type lesions [17]. Typical MRI findings in NMOSD include longitudinally extensive transverse myelitis, large confluent hemispheric lesions, lesions involving the dorsal medulla, long corticospinal tract lesions, thalamic and periependymal lesions, and optic nerve lesions extending over more than half the optic nerve or involving the optic chiasm [16].
- Cerebrospinal fluid (CSF) findings: Oligoclonal bands are commonly found in the CSF of patients with MS (90–95%) but are less frequently seen in NMOSD (20–30%) [18]. In addition, unlike MS, CSF tests in NMOSD often reveal elevated pleocytosis, occurring in about 35% of cases, with a predominance of neutrophils or eosinophils. Another distinguishing feature is the increased CSF level of interleukin-6 (IL-6) found in NMOSD. Absence of CSF oligoclonal bands supports a diagnosis of NMOSD over MS [18].
- Clinical features: Relapse patterns differ significantly between MS and NMOSD. An analysis of 75 NMOSD cases and 101 age- and sex-matched MS controls from Australia and New Zealand revealed that while spinal cord and optic neuritis attacks were common in both conditions, optic neuritis and area postrema relapses were more frequent in NMOSD. NMOSD relapses were more severe as shown by higher level and longer duration of disability and higher frequency (time between relapses was 10.6 months in NMOSD compared with

18.0 months in MS), often requiring acute immunotherapies and showing less complete recovery. In addition, the course of NMOSD is mainly relapsing without evidence of progression, while MS is characterized by progressive disability at different stages of the disease [19].

3.2.2 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

MOGAD shares many clinical features with NMOSD, including optic neuritis and myelitis. However, there are many distinguishing features:

- MRI characteristics: Both MOGAD and NMOSD show optic nerve lesions, but bilateral optic neuritis is more common in MOGAD (63% versus 25%) and perineural optic nerve enhancement is frequently seen. MOGAD often exhibits deep white matter lesions and leptomeningeal enhancement, which are less common in NMOSD [20]. NMOSD typically shows lesions in periependymal, periaqueductal, and hypothalamic areas, while cortical subcortical, and juxtacortical lesions are more frequent in MOGAD [20]. LETM is common in both MOGAD and NMOSD, but isolated conus medullaris lesions are more suggestive of MOGAD while cord atrophy is more pronounced in NMOSD. Resolution of spinal lesions is more common in MOGAD, whereas NMOSD lesions tend to persist.
- Serological testing: Serum AQP4-IgGs are highly specific for NMOSD and high titers MOG-IgG (> 1:100) are strongly suggestive of MOGAD. Low titers MOG-IgG (< 1:100) are nonspecific and can be seen in other CNS demyelinating disorders. In MOG-IgG seronegative patients with clinical and MRI features suggestive of MOGAD, CSF testing for MOG-IgG can be used to support the diagnosis [7].
- Clinical features: NMOSD is much more common in women compared with MOGAD with a female to male ratio of 9:1 and 1:1, respectively. Patients with MOGAD generally have a better prognosis and a higher likelihood of recovery from relapses compared with NMOSD [21]. Nearly 50% of patients with MOGAD follow a monophasic course as opposed to a relapsing course with NMOSD.

3.2.3 Acute Disseminated Encephalomyelitis

ADEM is a CNS inflammatory demyelinating disease that usually presents as a monophasic illness with multifocal neurological symptoms following an infection or vaccination. Key differences with NMOSD include:

Table 2 Comparative Clinical, Imaging, and Laboratory Features of NMOSD, MS, MOGAD, and ADEM

	NMOSD	MS	MOGAD	ADEM
Epidemiology	High female predominance (F/M ratio 9:1) Mean age of onset 25-35 years	Moderate female predominance(F/M ratio 3:1) Mean age of onset 40-45 years	No female predominance(F/M ratio (1:1) Age at onset: 0-40 years, more common in childhood	Age of onset: predominantly affects children
Clinical Features	NMOSD relapses are usually severe, often involving optic nerves and area postrema, with incomplete recovery The course is mainly relapsing without evidence of progression	Progressive disability at different stages of the disease.	Relapsing or monophasic course (50%) Better prognosis and higher likelihood of recovery from relapses than NMOSD. Papilledema on fundoscopy	Typically, monophasic Presence of encephalopathy No new symptoms, signs or MRI lesions after three months of initial ADEM
MRI Imaging	Longitudinally extensive transverse myelitis Optic nerve lesions extending more than half the optic nerve or involving the optic chiasm Dorsal medulla lesions Periependymal lesions Large confluent hemispheric lesions Central spinal cord lesions Spinal cord bright spotty lesions	Multifocal brain lesions, often located in periventricular, juxtacortical, and infratentorial regions MRI characteristics that suggest MS include periventricular lesions in the inferior temporal lobe, cortical/juxtacortical lesions, and Dawson's fingers Peripheral spinal cord lesions	Longitudinally extensive transverse myelitis Conus medullaris lesions Bilateral optic neuritis is more common in MOGAD compared to NMOSD (63 vs 25%) Perineural optic nerve enhancement ADEM-like fluffy lesions Leptomeningeal enhancement Resolution of lesions is more common in MOGAD	Confluent large fluffy white matter lesions Internal capsule and thalamic lesions T1 hypointense white matter lesions are rare
CSF Analysis	Oligoclonal bands are infrequently seen in NMOSD (20-30%) Pleocytosis, occurs in about 35% of cases, with a predominance of neutrophils or eosinophils	Oligoclonal bands are commonly found in the CSF (90-95%)	Oligoclonal bands are rarely found in CSF (10-20%) Pleocytosis, occurs in about 35% of cases	Oligoclonal bands are found in less than 10% and may be transitory CSF pleocytosis is observed in a wide range of patients (28–86%)
Serology	Serum AQP4 antibodies are highly specific for NMOSD		High titers anti-MOG antibodies (>1:100) are strongly suggestive of MOGAD	

ADEM Acute Disseminated Encephalomyelitis, *AQP4* Aquaporin-4, *CSF* Cerebrospinal Fluid, *F/M* Female to Male, *NMOSD* Neuromyelitis Optica Spectrum Disorder, *MOGAD* Myelin Oligodendrocyte Glycoprotein Antibody Disease, *MRI* Magnetic Resonance Imaging, *MS* Multiple Sclerosis

- Age of onset: ADEM predominantly affects children, while NMOSD can occur at any age but is more common in adults [20].
- Course of disease: ADEM is typically monophasic, whereas NMOSD is characterized by recurrent attacks [20, 22].
- MRI findings: Patients with ADEM exhibit brain lesions that closely resemble the confluent white matter lesions seen in NMOSD [23]. However, thalamic and internal capsule involvement could differentiate pediatric-onset NMOSD from ADEM [24].

3.3 Recommendations

- The diagnosis of NMOSD should be made on the basis of the IPND 2015 criteria.
- The differential diagnosis primarily includes MS, MOGAD, and ADEM, and requires a combination of clinical evaluation, antibody testing, and MRI characteristics to make a definite diagnosis.
- Cell-based assays, preferably live, are recommended in testing for AQP4-IgG and should be ideally obtained during a relapse before initiation of immunotherapy.

4 Treatment

4.1 Treatment of Relapses

Relapses in NMOSD are usually more severe than MS [22]. The outcome of untreated NMOSD relapses is poor, with only 21.6% of patients making a full recovery and 6% displaying no improvement at all [25]. However, prompt initiation of therapy in acute attacks and early escalation significantly improves outcomes.

The standard of care for acute attacks in both AQP4-IgG positive and dsNMOSD includes high-dose corticosteroids and plasma exchange (PE) [26]. Intravenous methylprednisolone (IVMP) is usually administered at a dose of 1000 mg per day for 3–5 days, followed by an oral corticosteroids taper (starting with 1 mg/kg/day and then tapered to 10–15 mg/day within 2–3 weeks). Low-dose oral corticosteroids, for up to 3–6 months, are beneficial in preventing early subsequent attacks, although there is a lack of prospective studies to support this approach [27]. The duration of low-dose corticosteroid maintenance treatment depends on the AQP4-IgG serostatus, disease activity, mode of action, and expected time to subsequent immunotherapy.

If patients do not respond adequately to methylprednisolone within the first few days, early rescue therapy with PE should be administered [25, 28–30]. Most studies with PE have been conducted with an average of five cycles either daily or every other day, although up to ten cycles have been used [25, 31]. Several retrospective studies have shown that early use of PE leads to better outcomes [25, 27, 28, 32, 33]; if initiated within 2 days of symptom onset, up to 40% of patients would make a full recovery, as opposed to 3.7% if treatment is delayed for 7 or more days [25, 34, 35]. Accordingly, early PE, preferably within 2 days of onset, either alone or as adjunctive therapy (add-on to corticosteroids,) should be considered in patients with disabling relapses [25]. In one study, patients with myelitis responded better to PE than IVMP as the initial therapy [25]. A repeated treatment course with either high-dose intravenous corticosteroids or PE improved outcomes and lowered the number of nonresponders [25].

No randomized controlled trials (RCTs) have investigated the effectiveness of intravenous immunoglobulin (IVIG) for acute NMOSD relapses, but IVIG may be a suitable option when PE is unavailable or contraindicated. A study showed that the combination of IVIG and high-dose corticosteroids led to higher chance of clinical recovery, whereas IVIG alone was linked with worsened clinical outcomes [36]. A recent study showed that PE was more effective than IVIG in reducing antibody concentrations as an add-on therapy in AQP4-IgG positive NMOSD patients [37].

Other therapeutic strategies such as early use of anti-CD20 or anti-complement therapies have been reported in single case series to lead to favorable outcomes in acute attacks [38–41]. Future therapies may also include antibodies against the neonatal Fc receptor, which are currently being studied in an open-label trial (NCT06497374).

4.2 Recommendations

- Treatment with high-dose corticosteroids and/or PE should be initiated as early as possible. Early treatment of relapses is essential for ensuring proper recovery.
- Patients with inadequate response to high-dose corticosteroids should be started on PE therapy early on.
- PE should be used as initial therapy, preferably within 2 days, in patients with:

  o Incomplete response to corticosteroids in previous relapses.
  o Adequate response to PE during previous relapses.
  o Disabling relapses.

- Combined treatment with high-dose corticosteroids and PE may be used in disabling relapses.

4.3 Long-Term Immunotherapy

Conventional immunosuppressants such as azathioprine (AZA), mycophenolate (MMF), methotrexate (MTX),

rituximab (RTX), mitoxantrone, and cyclophosphamide have been successfully used to prevent NMO relapses. Recently, four monoclonal antibodies have been evaluated in large randomized controlled trials, leading to their approval by regulatory agencies in the USA, Europe, and other countries. These include complement inhibitors (eculizumab and ravulizumab), IL-6 inhibitors (satralizumab), and a novel anti-CD19 monoclonal antibody (inebilizumab).

4.3.1 Treatment of Anti-AQP4-Positive NMOSD

Patients with AQP4-IgG-positive NMOSD are at increased risk of relapses [42, 43], and relapses are usually devastating with poor recovery [44] leading to increased mortality [45, 46]. Accordingly, relapse prevention is the cornerstone of management of AQP4-IgG-positive NMOSD. The panel agreed that all patients with AQP4-IgG-positive NMOSD should be treated with chronic immunosuppression to prevent relapses and preserve neurologic function. Various immunomodulators and immunosuppressants have been used, with variable efficacy and safety profiles. Traditional immunosuppressants, such as corticosteroids, azathioprine, mycophenolate mofetil, cyclophosphamide, and mitoxantrone, have been used for the past two decades for the management of NMO, and therefore have a longer track record of safety. In the past two decades, there has been increasing use of rituximab (anti-CD20) and tocilizumab (IL-6 inhibitor) as off-label therapies, both of which showed a high degree of efficacy. More recently, newly approved monoclonal antibodies have started to gain popularity, unfortunately limited by their expensive pricing.

4.3.1.1 Corticosteroids The long-term use of corticosteroids for relapse prevention in NMOSD should be discouraged owing to the associated adverse events. Most experts recommend maintaining oral prednisone (1 mg/kg/day) until an immunotherapy is initiated and has reached its expected efficacy before a slow taper is initiated. Care has to be taken in prescribing high-dose corticosteroids in elderly patients or patients at risk of osteoporosis and other corticosteroids complications [47]. Adjunct low-dose prednisone can be used as an add-on in selected cases if relapses are not controlled with conventional immunosuppressants and higher efficacy treatments are not available [48].

4.3.1.2 Conventional Immunosuppressants AZA, MMF, MTX, mitoxantrone, and cyclophosphamide have been successfully used to prevent NMO relapses [49–53]. The evidence of efficacy comes mostly from uncontrolled case series or retrospective case-controlled studies.

AZA is a purine synthesis inhibitor that interferes with cell proliferation, especially lymphocytes [54]. It is one of the most commonly used medications to prevent NMO

relapses. The optimum dosage of AZA in NMOSD is not well-studied, but most experts recommend 2–3 mg/kg/day [55, 56]. An increase in the red blood cell mean corpuscular volume (MCV) by 5 points above baseline has been associated with a lower risk of relapses [57]. The full biological effect of AZA is achieved around 4–6 months after treatment initiation. Accordingly, continued use of prednisone is recommended until AZA is fully effective [55]. A large-scale single-center study of patients with NMOSD (about 50% AQP4-IgG positive) showed that AZA reduced the risk of expanded disability status scale (EDSS) progression by 80% over a 5-year period [58]. One of the largest experiences with AZA in NMOSD to date was reported by Costanzi et al. who retrospectively reviewed 99 NMO/NMOSD cases treated with AZA over a 15-year period [57]. AZA, with or without corticosteroids, decreased annualized relapse rates from 2.20 to 0.52 over a median treatment duration of 22 months [57].

AZA has been shown in multiple studies to be inferior to rituximab and tocilizumab in preventing relapses and reducing disability [59–61]. In a randomized clinical trial, 54.3% of patients on AZA and 78.8% on rituximab were relapse-free [51]. In an open-label, multicenter, randomized phase 2 study (TANGO study) comparing the efficacy of tocilizumab and AZA in severe NMOSD, only 14% of patients in the tocilizumab group experienced a first relapse, compared with 47% in the AZA group (hazard ratio [HR] 0.236, 95% CI 0.107–0.518, $p < 0.0001$) [62].

The incidence of adverse events on AZA ranges from 6.5 to 43.8% [51, 57, 60, 63], including nausea, abnormal liver function tests, leukopenia, fatigue, hair loss, and diarrhea. Serious adverse events include hepatotoxicity, bone marrow suppression, and malignancies (lymphoma reported in 3% of patients) [57]. Cumulative doses of 600 g should not be exceeded owing to a possible increased risk of malignancy [64]. Thiopurine *S*-methyltransferase polymorphisms appear to modify the risk of side effects [65]. The risk of treatment failure on AZA is higher in patients with a history of severe relapses or a high annualized relapse rate (ARR) [66]. Compared with other steroid-sparing agents, azathioprine has the advantage of a lower cost and a good safety profile during pregnancy.

MMF is another commonly used immunosuppressant in the management of NMOSD. It is an inhibitor of inosine-5′-monophosphate dehydrogenase, which interferes with the proliferation of B and T lymphocytes. The efficacy of MMF has been established in multiple observational studies in both AQP4-IgG-positive and negative NMOSD. A meta-analysis involving 930 patients reported an average reduction in ARR of −1.17 [52]. Another study involving 200 patients found a mean decrease in ARR of 1.13, with a mean EDSS reduction of 0.85 points (95% CI 0.36–1.34) [67]. A study comparing low-dose RTX and MMF in Chinese patients

with NMOSD found that both treatments were effective and tolerable, although rituximab showed a better reduction in ARR [68]. MMF is commonly prescribed at a dose of 1500–3000 mg per day, targeting an absolute lymphocyte count of 1000–1500 cells/μL for maximal efficacy and minimal adverse events. MMF was associated with an increased risk of lymphoma in transplant patients and nonmelanoma skin carcinoma [69].

MTX, an inhibitor of dihydrofolate reductase, is considered a safe alternative to AZA and MMF, although it is less commonly used in NMOSD owing to the limited number of observational studies [70, 71]. A study involving 14 patients with NMOSD treated with MTX demonstrated a 64% reduction in ARR and a relapse freedom rate of 75% [50]. Potential side effects of MTX include bone marrow suppression and elevated liver function tests.

For severe and disabling relapses, pulse cyclophosphamide or mitoxantrone have been used with reported efficacy, mostly in small reports [49, 53]. Given the high toxicity of both agents, their use became limited to scenarios where other alternatives are unavailable.

4.3.1.3 Rituximab RTX is a chimeric monoclonal IgG antibody targeting the CD20 surface antigen on B lymphocytes. RTX has been one of the most effective therapies in NMOSD for the last two decades. It is approved in Japan for the prevention of relapses in patients with NMOSD but is still used off-label in other parts of the world on the basis of expert opinion and consensus guidelines [34, 54]. In a prospective open-label study of 30 patients treated with RTX, the relapse rate was reduced by 88%, and 70% of patients became relapse-free over 24 months [72]. Disability either improved or stabilized in 97% of patients and AQP4-IgG declined significantly. In a retrospective review of 100 patients with relapsing NMOSD treated with RTX for at least 6 months and a follow-up period of more than 5 years, ARR was reduced by 96% and disability improved or stabilized in 96% of patients [73].

An open label randomized controlled trial conducted in Iran included 86 patients with NMOSD (33 AQP4-IgG positive), randomized to receive either AZA or RTX [51]. The mean ARR in the AZA group decreased from 1 (0.38) to 0.51 (0.55) ($p < 0.001$) and from 1.30 (0.68) to 0.21 (0.42) in the RTX group ($p < 0.001$). Overall, 19 patients (54.3%) on AZA and 26 (78.8%) on RTX were relapse free ($p = 0.033$). The authors concluded that RTX was significantly more effective than AZA [51].

A multicenter, randomized, double-blind, placebo-controlled trial was conducted in AQP4-IgG-positive NMOSD patients in Japan (RIN-1 study) [74]. In total, 38 participants were randomly allocated to either rituximab ($n = 19$) or placebo ($n = 19$). Seven relapses occurred in the placebo group and none in the rituximab group ($p = 0.0058$). This study,

however, was limited by its small sample size and inclusion of participants with mild disease activity. A recent systematic review and meta-analysis of RTX in NMOSD included 29 studies and 732 patients [75]. It showed that RTX reduced both EDSS and ARR by an average of 0.57 (95% CI −0.69 to −0.44) and 1.57 (95% CI −1.78 to −1.35), respectively. Side effects of RTX include infusion reactions, infections (including progressive multifocal leukoencephalopathy with an estimated risk of 1:20,000), myelosuppression, hepatitis B, and tuberculosis reactivation [76]. Hypogammaglobulinemia remains a concern, especially with long-term use [77]. A retrospective study of 169 patients with NMOSD treated with RTX found that serum IgG levels declined significantly after 2 years, dropping by 2–8% annually for 8 years before plateauing at 10 years [78]. The proportion of patients with low IgG (< 6 g/L) increased from 1.2% after 1 year to 41% after 14 years.

The dosing of RTX in NMOSD has been variable across centers varying from 500 to 2000 mg administered every 6–12 months. A study comparing 2000 and 1000 mg every 6 months in 161 patients with NMOSD or MS found that the rate of B-cell repopulation was similar between the two groups and concluded that 1000 mg every 6 months was sufficient [79].

A retrospective analysis showed that extended interval dosing of RTX guided by B-cell repopulation (> 1%) had a similar effect on relapse rate compared with the standard every 6 months dosing in patients with AQP4-IgG-positive NMOSD [80]. It is of note that in this study each RTX cycle consisted of 2000 mg. An observational study involving 37 patients, 73% of whom were AQP4-IgG positive, found that the ARR after RTX treatment was significantly low (0.136). The RTX dosing regimen consisted of an initial 1000 mg dose followed by maintenance doses of 500 mg every 6 months or upon B-cell repopulation [81]. Another retrospective analysis of 136 patients with NMOSD treated with RTX in China showed that an ultralow-dose regimen (100–300 mg based on B-cell repopulation was not inferior in relapse prevention to a low-dose regimen (500 mg every 6 months) [82]. Another large prospective study examined the efficacy of low-dose RTX administered at a dose of 100 mg once weekly for 3 weeks as induction therapy, followed by maintenance of 100 mg once every 6 months according to the percentages of circulating B-cell subsets and patient's preference [83]. There was a significant reduction in ARR, with a 67.6% relapse-free rate. Rather than dosing by the total CD19-positive B-cells, Bruschi et al. suggested that dosing on the basis of CD27-positive memory B cells has resulted in fewer infusions while maintaining efficacy [84].

4.3.1.4 Inebilizumab Inebilizumab was approved as monotherapy in adults with AQP4-IgG-positive NMOSD. It is a humanized monoclonal antibody that depletes B lympho-

cytes by binding to the CD19 molecule leading to broader depletion of B-cell lineages, including plasma blasts, potentially offering a higher efficacy than anti-CD20 agents [85]. It also offers an advantage over RTX in patients with FCGR3A polymorphisms, who are relatively resistant to RTX. The recommended initial dosing consists of two 300 mg intravenous infusions administered 2 weeks apart followed by a single dose of 300 mg, every 6 months [34, 86, 87]. In a phase II/III placebo-controlled study (N-Momentum), 12% of patients on inebilizumab sustained a relapse compared with 39% receiving placebo (HR 0.272, 95% CI 0.150–0.496, $p < 0.0001$). These results were particularly significant in the anti-AQP4-positive group (11% versus 42%; HR 0.227, 95% CI 0.121–0.423, $p < 0.0001$) [88]. Mean EDSS scores improved with longer-term treatment. In 13 patients with prior use of rituximab, the ARR on inebilizumab was similar to that of participants without prior rituximab use (0.08 versus 0.10) [89]. Treatment efficacy in the AQP4-IgG group could not be determined owing to the small sample size [88, 90]. Serious adverse events occurred in 5% of patients receiving inebilizumab and 9% of patients on placebo, with two deaths in the open-label period, one in each arm. Inebilizumab may have a potential advantage over RTX owing to its different biological targets. Among the 17 participants in the trial who were initially treated with RTX, 13 were randomly assigned to the inebilizumab treatment group. ARR was reduced from 0.78 to 0.08 upon switching to inebilizumab. Treatment efficacy was comparable for patients with and without prior RTX use.

The long-term efficacy and safety of inebilizumab was investigated in 75 AQP4-IgG-positive patients with NMOSD receiving treatment for more than 4 years (mean treatment duration of 4.6 years), as an open-label extension of the N-Momentum trial [91]. Overall, 65 patients were initially assigned to the inebilizumab group and 10 to the placebo group. A total of 83% were relapse free with stable levels of disability throughout the study extension. Inebilizumab was well-tolerated, with only 2.7% of patients experiencing serious and treatment-related side effects. No deaths or progressive multifocal leukoencephalopathy (PML) cases were reported during the extension period.

Before starting RTX or inebilizumab, it is essential to exclude any active infection and screen for latent infections including hepatitis B and C and tuberculosis. Ensure that vaccinations are up to date, particularly live vaccines. Any live vaccines should be administered 4 weeks before therapy as they are contraindicated during treatment [92].

4.3.1.5 Eculizumab and Ravulizumab Eculizumab was the first US Food and Drug Administration [92] approved therapy for adults with AQP4-IgG-positive NMOSD [92] and is currently available in many countries in the MENA region. It is a monoclonal antibody specifically targeting complement protein C5, blocking its cleavage into C5a and preventing the formation of the membrane attack complex [93]. The clinical efficacy of eculizumab was established in the PREVENT trial, a randomized, double-blind placebo-controlled trial, including 143 AQP4-IgG-positive patients with NMOSD [2]. Patients on eculizumab showed a 94.2% reduction in relapse rate compared with placebo over 4 years, although MRI was not used to adjudicate events (NCT01892345). There were no cases of meningococcal infection during the trial. The recommended dosing of eculizumab is 900 mg intravenous (IV) weekly for 4 weeks followed by 1200 mg IV biweekly [94].

Following the approval of eculizumab, both the FDA and the European Medicines Agency [25] approved ravulizumab, a humanized, long-lasting complement inhibiting monoclonal antibody, for the treatment of adults with AQP4-IgG-positive NMOSD. Ravulizumab is currently available in many countries in the MENA region. Ravulizumab was bioengineered by substituting four amino acids in the eculizumab heavy chain frame which extended its half-life, allowing its administration every 8 weeks [95]. A phase 3, open-label clinical trial (CHAMPION-NMOSD) compared 58 patients with AQP4-IgG-positive NMOSD to the 47 patients in the placebo arm of the PREVENT trial [96]. None of the patients in the treatment arm had a relapse after a minimum of 50 weeks (compared with 20 in 47 PREVENT placebo patients during the same period of time). MRI was required to adjudicate events in this study. A network meta-analysis on the trials data of eculizumab, inebilizumab, and satralizumab, suggested that complement inhibition with eculizumab may be more effective in preventing NMOSD attacks than treatment with inebilizumab or satralizumab [97]. The safety profile was acceptable with two patients developing a meningococcal infection. The recommended dosing of ravulizumab is weight-based and is administered intravenously every 8 weeks [95].

Both eculizumab and ravulizumab have a rapid onset of action and induce continuous near-complete inhibition of C5 activity after the first infusion [98].

As with all complement-inhibiting therapies, patients should be vaccinated against *N. meningitidis* at least 2 weeks prior to the first infusion. Alternatively, if therapy needs to be started urgently, patients must receive antibiotic prophylaxis until at least 2 weeks after completed vaccination [99]. In patients receiving long-term eculizumab therapy, meningococcal vaccination should follow current recommendations, including booster doses of the MenACWY vaccine every 5 years for the duration of treatment [100]. Vaccination and/or antibiotic prophylaxis reduces but does not eliminate the risk of invasive meningococcal infection; therefore, careful clinical vigilance and patient education regarding early symptoms of meningococcal disease are required.

4.3.1.6 Satralizumab and Tocilizumab
Interleukin 6 (IL-6) is known to be elevated in NMOSD. It plays a vital role in the survival of plasma blasts, increases their secretion of AQP4-IgG [101] and contributes to the dysfunction of the blood–brain barrier allowing for increased leukocyte transmigration [102]. A phase 2 open-label randomized trial (TANGO) conducted in China compared IV tocilizumab (8 mg/kg every 4 weeks), an anti-IL-6R monoclonal antibody, and AZA in patients with NMOSD. More than 85% of the patients were AQP4-IgG positive. Tocilizumab significantly prolonged the time to relapse (median of 78.9 weeks versus 56.7 weeks in AZA) and reduced the relapse rate to 14% compared with 47% with AZA [62]. A subcutaneous formulation of tocilizumab appears to be effective on the basis of findings from a small retrospective series involving seven patients with AQP4-IgG-positive NMOSD [103]. It is of note that the use of tocilizumab for NMOSD is considered off-label in most countries.

Satralizumab is a humanized anti-IL-6 receptor monoclonal antibody approved for the treatment of AQP4-IgG-positive NMOSD in adults and children aged ≥ 12 years [104]. The recommended dose is 120 mg by subcutaneous injection at weeks 0, 2, and 4, and then every 4 weeks thereafter [104].

The SAkuraSky trial was a phase 3, randomized, double-blind, placebo-controlled clinical trial which included patients aged between 12 and 74 years and who had either AQP4-IgG positive or negative NMOSD [105]. Satralizumab was added to baseline immunosuppressive treatments, which included AZA, MMF, and oral corticosteroids, while the use of anti-CD20 agents was not authorized before study enrollment. The study met its primary endpoint with a lower proportion of patients experiencing a first relapse compared with placebo (HR 0.38, 95% CI 0.16 to 0.88, $p = 0.02$) [105]. The SAkuraStar trial was a phase 3, international, randomized, double-blind, placebo-controlled study of satralizumab as monotherapy for the treatment of patients, aged between 18 and 74 years, who had either AQP4-IgG-positive or AQP4-IgG-negative NMOSD [106]. Satralizumab was associated with a significant reduction in relapse rate compared with placebo (HR 0.45, 95% Cl 0.23 to 0.89, $p = 0.018$). Similar results were obtained in a Japanese real-world cohort ($n = 131$) in which 95.4% of patients on satralizumab were relapse-free over a median duration of 197 days [107]. Satralizumab had a favorable safety profile, as the incidence of serious adverse events and adverse events leading to withdrawal was similar between the two arms in both trials [105, 106]. The safety profile of satralizumab, whether as monotherapy or in combination with immunosuppressive treatments, was unchanged during the open-label extension, with most adverse events being mild to moderate [108, 109]. The most common adverse events were nasopharyngitis and upper respiratory and urinary tract infections. Injection-related reactions were mild and did not lead to treatment discontinuation. Drops in neutrophil and platelet counts, and elevations in liver enzymes, were transient [108]. It is recommended that patients receive all appropriate vaccinations before starting satralizumab. Screening for tuberculosis is also advised prior to initiation.

4.3.1.7 Autologous Hematopoietic Stem Cell Transplantation
Autologous hematopoietic stem cell transplantation (AHSCT) is an emerging therapeutic approach for NMOSD. The process involves harvesting hematopoietic stem cells from the patient's bone marrow or peripheral blood followed by high-dose chemotherapy to ablate the existing immune system. The collected stem cells are reintroduced into the patient's body to regenerate a new, less autoreactive immune system. AHSCT is typically reserved for patients with severe, refractory NMOSD who have not responded adequately to standard treatments [5].

In a retrospective multicenter study, the European Society for Blood and Marrow Transplantation (EBMT) assessed the efficacy and safety of AHSCT in 16 patients with NMOSD refractory to treatment [110]. After a median follow-up of around 4 years, 3 patients were disease-free while 13 required further treatments owing to relapses or disability progression.

Burt et al. enrolled 12 patients with NMOSD without other associated autoimmune disorders (11 were AQP4-IgG positive) in a prospective open-label trial of AHSCT. Out of 11 patients with more than 5 years of follow-up, 80% were free of relapses and off treatment. Interestingly, 9/11 AQP4-IgG-positive patients became seronegative [111].

AHSCT represents a promising option for patients with refractory NMOSD, offering potential long-term remission and improved quality of life. However, owing to the risks involved, it is crucial to carefully select appropriate candidates and provide thorough pre- and post-transplant care. In case of breakthrough disease on at least two monoclonal antibodies, including a complement inhibitor, patients should be referred to a specialized center for the possibility of AHSCT. Anti-BCMA CAR-T cell therapy represents a promising emerging option for refractory cases in the future [112].

4.3.1.8 Switching Therapies
Studies on switching between immunotherapies in NMOSD are limited. Switching treatment is usually because of breakthrough disease or side effects. In case of breakthrough disease, the most common switch is from RTX, which is widely used in the MENA region, to one of the newly approved monoclonal antibodies. In the PREVENT and CHAMPION-NMOSD trials a minimal washout period of 3 months was required before shifting from RTX to eculizumab or ravulizumab, respec-

tively [2, 96]. Safety analysis did not show any increase in risk of infection. The MOMENTUM, TANGO, and SAkura trials required a minimal washout period of 6 months before shifting from RTX to inebilizumab, tocilizumab, and satralizumab, respectively, and did not show any major safety concerns [62, 88, 105]. However, when switching therapies because of breakthrough disease, it is probably unsafe to go for 3–6 months washout periods. Earlier switching, taking into consideration the patient's age, relapse severity, previous drug half-life, and time to onset of action of the new treatment, would be more appropriate. In case of breakthrough disease on conventional immunosuppressants, a direct switch to monoclonal antibody therapy without prolonged washout is generally recommended, as a long treatment gap carries high relapse risk. When switching from conventional immunosuppressants because of infection, intolerance, bone marrow suppression, or hepatotoxicity, conventional agents should be discontinued immediately and another therapy initiated once infection or toxicity is controlled. Overlap with low-dose prednisone during the transition period may be used until the biologic reaches therapeutic levels.

4.3.1.9 Recommendations

- The monoclonal antibodies rituximab, eculizumab, ravulizumab, inebilizumab, tocilizumab, or satralizumab should be offered as first-line therapy in patients with AQP4-IgG-positive NMOSD on the basis of availability and affordability.
- Rituximab is off-label in most countries but widely used owing to cost considerations.
- Rituximab redosing on the basis of B-cell repopulation is acceptable but should be carried out in specialized centers with expertise in managing NMOSD.
- In patients with disabling relapses or poor recovery, complement inhibitors can be offered as first-line therapy as they have shown probably the highest efficacy in the initial trials, although comparing different trials with different study populations, inclusion criteria, and relapse definitions is not ideal.
- The use of conventional immunosuppressants as monotherapy should be limited to patients who are stable on them or unable to receive monoclonal antibody therapies.
- Breakthrough disease was defined as a relapse during therapy despite sufficient time to expect full action.
- In case of disease breakthrough on conventional immunosuppressants, escalation to one of the monoclonal antibodies is recommended.
- In case of disease breakthrough on a monoclonal antibody, switching to another monoclonal antibody with a different mechanism of action is recommended. Conventional immunosuppressants can also be used as an add-on

if other monoclonal antibodies are inaccessible or unaffordable.
- Maintenance with oral prednisone (1mg/kg/day) is recommended following the first relapse or upon switching therapies until a long-term treatment is initiated and has reached its expected efficacy before a slow taper is initiated.

4.3.2 Discontinuation of Immunotherapy

NMOSD often requires long-term immunosuppressant therapy to prevent relapses. However, there is no consensus about treatment duration. The main concern in discontinuing therapy is the risk of relapse, as a single relapse can result in significant disability. A recent French study showed that RTX de-escalation (including increased infusion intervals or switching to oral therapies) or discontinuation in AQP4-IgG-positive and dsNMOSD patients is associated with increased risk of relapses in the following 12 months [113]. A study involving 17 patients with AQP4-IgG-positive NMOSD who discontinued immunosuppressive therapies after being relapse-free for at least 3 years found that approximately 82% experienced a relapse. Notably, relapses occurred even in patients who had remained relapse-free for 5 years before stopping treatment [114]. However, few other studies reported prolonged disease-free periods off treatment [115]. Pandit et al. reported remissions for up to 20 years in AQP4-IgG-positive patients off treatment [116]. Prolonged remissions were also reported in a few cases following discontinuation of rituximab [117]. However, such cases are rare, and the long-term risks of immunotherapy are small compared with the risk of a new disabling relapse in AQP4-IgG-positive disease.

4.3.3 Recommendations

- In patients with AQP4-IgG-positive NMOSD, treatment should be maintained for as long as possible.
- Patients not receiving treatment should be closely monitored for any evidence of disease reactivation.

4.3.4 Treatment of dsNMOSD

Patients with dsNMOSD and inflammatory features (acute onset, typical imaging, CSF oligoclonal bands [OCB], coexisting autoimmunity, steroid and PE response, etc.) as opposed to genetic, metabolic, or other causes, can be divided into monophasic (around 10%) and relapsing groups.

4.3.5 Choice of Disease-Modifying Therapy (DMT) in Relapsing dsNMOSD

No treatment is currently approved for dsNMOSD. The pivotal trials of satralizumab and inebilizumab included

dsNMOSD cases but the numbers were too small to draw any conclusions. Since the underlying mechanisms of inflammation can be heterogeneous, it is logical to use broad conventional immunosuppressants with effect on both T- and B-cell pathways. Typically, these include corticosteroids, MMF, AZA, and MTX [34, 118]. Alternatively, a B-cell depleting therapy such as RTX is reasonable. In a multicenter retrospective study of patients with dsNMOSD treated with RTX or MMF, ARR declined from 1.93 to 0.12 and from 1.45 to 0.30, respectively [119]. In another retrospective review of 74 patients with dsNMOSD, ARR decreased from 0.3 to 0.2 on RTX, from 0.9 to 0.5 on AZA, and from 0.9 to 0.4 on MMF [120]. In patients with breakthrough disease on first-line therapies, tocilizumab has been shown to be effective [121]. If relapses occur on these therapies, tocilizumab, a combination of rituximab and oral immunosuppressants, cyclophosphamide, mitoxantrone, or AHSCT can be tried.

4.3.6 Should DMT Be Initiated after the First Attack in dsNMOSD?

Initiating long-term DMT after the very first relapse in dsNMOSD is controversial as some patients may have only a one-off event, e.g., a post-infectious or post-vaccination demyelinating episode [34, 122]. Some cases may not even be inflammatory. There are currently no reliable predictors of future relapses in dsNMOSD. However, the panel felt that in view of the disabling nature of NMOSD relapses, treatment should be offered early on irrespective of serostatus. Careful clinical and MRI follow up is required in patients on no treatment. An arbitrary clinical and radiologic follow up of 5 years is considered reasonable before labeling dsNMOSD as monophasic and discontinuing follow-up [4].

4.3.7 Recommendations

- Initiate treatment in patients with dsNMOSD following the first attack.
- Perform regular assessment to determine the need for continued treatment in patients with persistent dsNMOSD presenting with a monophasic course.
- Initiate treatment with rituximab, mycophenolate, azathioprine, or methotrexate
- In case of breakthrough disease, tocilizumab, a combination of rituximab and oral immunosuppressants, cyclophosphamide, or AHSCT can be tried. Eculizumab, ravulizumab, or satralizumab can also be used.

5 Special Populations

5.1 Pediatric NMOSD

NMOSD is rare in the pediatric group accounting for around 3–5% of cases [123]. Pediatric patients have been poorly represented in the pivotal trials of new monoclonal antibodies. In the absence of class I evidence, treatment of children with NMOSD relies on data from observational retrospective studies. In a retrospective review of 91 children with NMOSD (AQP4-IgG-positive or dsNMOSD), the most commonly used treatments were RTX ($n = 38$), MMF ($n = 16$), AZA ($n = 15$), and IVIG ($n = 9$) [124]. Patients on RTX and MMF had the lowest ARR, followed by azathioprine and IVIG: 0.25, 0.33, 0.40 and 0.54, respectively.

In a multicenter retrospective study of 16 children with NMOSD, RTX led to significant reduction in ARR ($p = 0.003$) [125]. Six patients were relapse-free during a mean follow-up of 6.1 years (range 1.6–13.6). Most relapses were associated with B-cell repopulation or depletion failure. In another observational study, five children with NMOSD had significant reductions in relapse rate on RTX. The attacks were also related to B-cell repopulation [125]. B-cell repopulation is highly variable in pediatric patients and is dose dependent. Monitoring of B-cell levels and individualized redosing has been suggested [126]. RTX has been used in pediatric patients for other indications and has overall a good safety profile in this age group. In a study following 144 children with various autoimmune and inflammatory disorders receiving RTX, adverse events occurred in 7.6% of patients including two deaths [127]. None had PML.

Satralizumab is a humanized anti-IL-6 receptor monoclonal antibody approved for the treatment of AQP4-IgG-positive NMOSD in adults and children aged ≥ 12 years [104]. However, there is limited experience in using satralizumab as a first-line therapy for adolescents with NMOSD (four adolescents in SAkuraStar and none in the SAkuraSky trials).

Tocilizumab is approved for pediatric use for treatment of systemic juvenile arthritis and polyarticular juvenile idiopathic arthritis. Breu et al. reported on two female adolescents with AQP4-IgG-positive NMOSD who relapsed under RTX therapy and clinically stabilized after switching to tocilizumab at a dose of 8 mg/kg [128]. The recommended pediatric dose of tocilizumab in juvenile rheumatoid arthritis and other autoimmune disorders is 8–12 mg/kg [129].

A single case report of a 12 year old child with severe AQP4-IgG-positive NMOSD and initial worsening on high dose IV methylprednisolone and plasma-exchange, reported significant improvement of symptoms with gradual recovery over 10 weeks following treatment with eculizumab with two weekly doses of 600 mg followed by maintenance dosage of

900 mg at week 3 and every 2 weeks thereafter [130]. Serum AQP4-IgG titer dropped from > 1:100000 to 1:100. Eculizumab has also been used in pediatric patients with atypical hemolytic uremic syndrome and showed a good safety profile [131]. As in adults, treatment should be preceded by meningococcal vaccine and/or antibiotic prophylaxis.

Ravulizumab has also been used in pediatric patients with atypical hemolytic uremic syndrome and has shown a good safety profile with the most common side effects being upper respiratory tract infection (40%) and oropharyngeal pain (30%) but no cases of meningococcal infections or deaths. Dosage and dosing intervals used were on the basis of patient weights [132]. No efficacy can be reported in NMOSD pediatric groups owing to lack of trials and case reports.

Another single case report of a 14-year-old boy with NMOSD and no improvement on IV methylprednisolone and IVIG, reported complete recovery on plasma-exchange followed by maintenance on prednisolone and satralizumab (120 mg/dose for 4 weeks). The child was relapse-free for 24 months [133].

There are currently no reports on the use of inebilizumab in pediatric patients with NMOSD or other autoimmune diseases. I-CAN is an ongoing phase II trial evaluating the safety of inebilizumab in patients between the age of 2 and 18 years (NCT05549258).

Owing to the rarity of NMOSD in children, no clear guidelines regarding treatment discontinuation are available in literature. However, in the large pediatric NMOSD cohorts reported, treatment was generally maintained [126, 134].

Acute relapses in children are usually managed like those in adults, with IVMP and PE. The latter has also been shown to be effective and safe in pediatric NMOSD [135].

5.2 Recommendations

- Pediatric patients with NMOSD can be treated initially with rituximab, mycophenolate, azathioprine, or methotrexate.
- In case of breakthrough disease on oral immunosuppressants, escalation to rituximab is recommended.
- Children above 12 years of age can be initiated on or escalated to satralizumab.
- In selected cases, especially in the case of breakthrough disease on initial therapies, ravulizumab, eculizumab, tocilizumab, or satralizumab can be used.

5.3 Pregnancy and Breastfeeding

AQP4-IgG NMOSD has a strong female predominance (9:1 ratio), with a mean age at onset of 30–40 years, i.e., during active childbearing years [136].

5.3.1 Impact of NMOSD on Pregnancy

NMOSD pregnancies are considered high risk, with studies reporting increased rates of miscarriage, intra-uterine growth retardation, pre-eclampsia, and eclampsia [137–142]. AQP4-IgG is expressed in the placenta and its binding by antibodies could lead to local inflammation and placental dysfunction [143]. AQP4-IgG can passively cross the placenta in the 2nd and 3rd trimesters and is detected in the newborn serum up to 3 months of age without clinical evidence of disease [143–145].

5.3.1.1 Impact of Pregnancy on NMOSD
Most reports point to an increased risk of relapse during pregnancy, especially in the last trimester, with a marked increase in the postpartum period [138, 142, 146–149]. A higher risk of relapses during pregnancy and postpartum is associated with higher disease activity in the pre-pregnancy year, reduction or discontinuation of treatment, younger age at disease onset, and higher titers of AQP4-IgG [148]. According to a recently published French consensus of recommendations for pregnancy management in NMOSD, conception is advised after at least 12 months of disease stability [150]. On the basis of the aforementioned, high relapse rates and the discontinuation of treatment before attempting conception carries a significant risk of relapses and disability [151] during pregnancy and the postpartum period. APS can be confused with hyperemesis gravidarum in early pregnancy since both cause severe nausea and vomiting. The area postrema is also implicated in the pathophysiology of hyperemesis gravidarum, particularly through the hormone GDF-15, which is produced by the placenta and binds to receptors in the area postrema.

5.3.1.2 Treatment of NMOSD during Pregnancy
AZA can be safely used during pregnancy [152, 153]. MMF and methotrexate are teratogenic [154–157] and should be discontinued before attempting conception. Non-fluorinated corticosteroids can be used alone or as add-on with other therapies, such as AZA, after careful benefit/risk ratio assessment. Corticosteroids may cause cleft palate if used during the first trimester and have been associated with intrauterine growth retardation and prematurity, and should be administered at the lowest effective dose [143].

Monoclonal antibody therapies provide a reasonable option for use during pregnancy planning [158]. IgG monoclonal antibodies do not cross the placenta during the first trimester, with active transfer beginning slowly at week 16 [159]. Owing to its long-lasting biological effect, pregnancy may be attempted 1 month after RTX infusion with minimal potential of fetal exposure, while offering an immunomodulatory benefit for several additional months [160]. In a systematic review of 121 pregnancies in which RTX was used

a few weeks prior to or during pregnancy, 88 resulted in live births, 12 in spontaneous abortions, and 3 were preterm. B-cell counts were low in 39% of newborns but normalized within 6 months [161]. A German cohort of pregnant women exposed to anti-CD20 agents during pregnancy reported an increase in preterm births [162]. Another study of 153 pregnancies with maternal exposure to RTX, reported 90 live births, 22 preterm infants, and one neonatal death. Eleven neonates had hematologic abnormalities, four had infections, and another two had congenital anomalies [163]. In infants of mothers treated with anti-CD20 therapies, live vaccines (but not non-live vaccines) should only be administered after repletion of B-cells [58].

Satralizumab and inebilizumab product labels advise against use during pregnancy [164]. Data on pregnancy outcomes with satralizumab and inebilizumab are very limited. However, inebilizumab, like RTX, has the advantage of a prolonged biological activity and may be discontinued 1 month prior to conception.

A period of 3 months is usually required between the last infusion of tocilizumab and attempting conception [150]. However, tocilizumab has been used during pregnancy in women with rheumatoid arthritis without an increased risk of congenital malformations, although the risk of spontaneous abortion and preterm birth was slightly elevated [165].

In a retrospective review of 75 pregnant women with atypical hemolytic uremic syndrome, treatment with eculizumab was safe [166]. In another study of 24 pregnant women with paroxysmal nocturnal hematuria treated with eculizumab, 85% had live births without evidence of congenital anomalies. Eculizumab's half-life is ~12 days and can be given during pregnancy after a strict benefit/risk assessment [142]. Ravulizumab has a similar molecular structure to eculizumab and can probably be continued during pregnancy if benefits outweigh risks [34].

5.3.1.3 Treatment of NMOSD Relapses during Pregnancy
IVMP in short courses is considered safe during pregnancy. There might be an increased risk of cleft lip and palate with the use of corticosteroids during the first trimester [167–171]. PE can also be used safely during pregnancy. Risks and adverse events associated with PE appear to be similar with or without pregnancy [160, 172, 173].

5.3.1.4 Postpartum Management and Breastfeeding
Because of the high postpartum relapse rate, early resumption of immunotherapy after delivery is recommended [150]. The use of rituximab within 2 weeks of delivery reduced the risk of relapse to as low as 8.3% [34]. Monoclonal antibodies are large molecules, and therefore their transfer to breast milk is minimal. Moreover, whatever is transferred to the infant will likely be destroyed in the gastrointestinal tract. The colostrum, however, secreted during the first 7-10 days postpartum, is rich in antibodies, mostly IgA. Accordingly, monoclonal antibodies can be safely resumed in breastfeeding women with NMOSD 10–14 days post-delivery.

Very low or undetectable concentrations of AZA have been found in breastfed children of mothers taking AZA, with reassuring post-marketing safety data [174]. MMF and MTX are low-molecular-weight molecules and are easily transferable to breast milk. It is not recommended to use either one during breastfeeding.

5.3.1.5 Recommendations

- Pregnancy may be attempted after at least 12 months of disease stability.
- Conception can be attempted 1 month after the administration of rituximab or inebilizumab. Their long biological effect might control disease reactivation during pregnancy.
- Immunotherapy should not be discontinued or delayed when attempting conception.
- Rituximab, eculizumab, ravulizumab, and tocilizumab can be continued during pregnancy if benefits outweigh risks after a thorough discussion with the patient.
- Azathioprine can be continued during pregnancy.
- Mycophenolate mofetil and methotrexate are teratogenic and should be discontinued prior to conception.
- There are no special recommendations regarding anesthesia type during delivery, including epidural and spinal anesthesia.
- In case of fetal exposure to B-cell depleting therapies during pregnancy, we recommend testing for lymphocyte and B-cell counts in the newborn.
- If anti-CD20 therapies are continued during pregnancy, live attenuated vaccines should not be administered to infants before B-cell repletion.
- In case of treatment interruption during pregnancy, immunotherapy should be resumed shortly after delivery.
- Monoclonal antibodies can be administered safely to breastfeeding mothers 7–10 days after delivery.

6 Conclusions

With the emergence of MOGAD as a distinct entity and the approval of new therapies for NMOSD, diagnostic and treatment algorithms continue to evolve. Our current consensus guidelines synthesize current evidence and expert opinion to support accurate diagnosis and timely, effective treatment in the MENA region. Updated international diagnostic criteria incorporating recent advances and MOGAD are forthcoming.

Declarations

Conflict of Interest The manuscript represents the views and opinions of the members involved in the development of the guidelines. All authors declare that they have no conflicts of interest related to the content of this manuscript.

Authors' Contributions All authors participated as members of the panel of experts in the meetings that led to the development of the manuscript. All authors actively contributed to the discussion and the consensus reached and drafted part of the manuscript. Bassem Yamout and Maya Zeineddine drafted the initial version of the manuscript and all authors discussed and reviewed the final version of the manuscript. All authors read and approved the final submitted manuscript and agree to be accountable for the work.

Ethics Approval Not applicable.

Consent to Participate Not applicable.

Consent for Publication Not applicable.

Availability of Data and Material Not applicable.

Code Availability Not applicable.

References

1. Shumway CL, Patel BC, Tripathy K, De Jesus O. Neuromyelitis optica spectrum disorder (NMOSD). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.

2. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–25.

3. Kim SM, Kim SJ, Lee HJ, Kuroda H, Palace J, Fujihara K. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2017;10(7):265–89.

4. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89.

5. Nabizadeh F, Masrouri S, Sharifkazemi H, Azami M, Nikfarjam M, Moghadasi AN. Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. J Clin Neurosci. 2022;105:37–44.

6. Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088–94.

7. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria. Lancet Neurol. 2023;22(3):268–82.

8. Zara P, Dinoto A, Carta S, Floris V, Turilli D, Budhram A, et al. Non-demyelinating disorders mimicking and misdiagnosed as NMOSD: a literature review. Eur J Neurol. 2023;30(10):3367–76.

9. Oreja-Guevara C, Brownlee W, Celius EG, Centonze D, Giovannoni G, Hodgkinson S, et al. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence. Mult Scler Relat Disord. 2023;69:104459.

10. Jeyalatha MV, Therese KL, Anand AR. An update on the laboratory diagnosis of neuromyelitis optica spectrum disorders. J Clin Neurol. 2022;18(2):152–62.

11. Carnero Contentti E, Rotstein D, Okuda DT, Paul F. How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder. Mult Scler. 2025;31(1):8–22.

12. Paudel S, Nepal G, Guragain S, Shah S, Paudel BS, Ojha R, et al. Longitudinally extensive transverse myelitis: a retrospective study differentiating neuromyelitis optica spectrum disorder from other etiologies. Cureus. 2021;13(3):e13968.

13. Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72(1):81–7.

14. Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, et al. Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology. 2018;91(17):e1642–51.

15. Montalban X, Lebrun-Frénay C, Oh J, Arrambide G, Moccia M, Pia Amato M, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850–65.

16. Rodríguez Y, Restrepo L, Chang C, Anaya J-M. Chapter 33 - Neurologic autoimmune diseases. In: Chang C, editor. Allergic and immunologic diseases. Academic Press: Berlin; 2022. p. 887–975.

17. Seok JM, Cho W, Chung YH, Ju H, Kim ST, Seong J-K, et al. Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorder using a deep learning model. Sci Rep. 2023;13(1):11625.

18. Wildner P, Stasiołek M, Matysiak M. Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. Mult Scler Relat Disord. 2020;37:101452.

19. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68(8):603–5.

20. Salama S, Khan M, Shanechi A, Levy M, Izbudak I. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler. 2020;26(14):1854–65.

21. Carnero Contentti E, López PA, Criniti J, Pettinicchi JP, Cristiano E, Patrucco L, et al. Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America. Mult Scler Relat Disord. 2023;72:104611.

22. Khalilidehkordi E, Clarke L, Arnett S, Bukhari W, Jimenez Sanchez S, O'Gorman C, et al. Relapse patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation. Front Neurol. 2020;11:537.

23. Kim W, Kim SH, Huh SY, Kim HJ. Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int. 2012;2012:735486.

24. Bulut E, Karakaya J, Salama S, Levy M, Huisman T, Izbudak I. Brain MRI findings in pediatric-onset neuromyelitis optica spectrum disorder: challenges in differentiation from acute disseminated encephalomyelitis. AJNR Am J Neuroradiol. 2019;40(4):726–31.

25. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79(2):206–16.

26. Akaishi T, Takeshita T, Himori N, Takahashi T, Misu T, Ogawa R, et al. Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD. Front Neurol. 2020;11:932.

27. Wang L, Du L, Li Q, Li F, Wang B, Zhao Y, et al. Neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: outcome prediction models. Front Immunol. 2022;13.

28. Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009;15(4):487–92.

29. Siritho S, Nopsopon T, Pongpirul K. Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. J Neurol. 2021;268(12):4549–62.

30. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878–86.

31. Boedecker SC, Luessi F, Engel S, Kraus D, Klimpke P, Holtz S, et al. Immunoadsorption and plasma exchange—efficient treatment options for neurological autoimmune diseases. J Clin Apher. 2022;37(1):70–81.

32. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e504.

33. Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflammation. 2019;6(4):e572.

34. Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)—revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024;271(1):141–76.

35. Demuth S, Guillaume M, Bourre B, Ciron J, Zephir H, Sirejacob Y, et al. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. J Neuroinflammation. 2022;19(1):62.

36. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20(4):501–4.

37. Siwach G, Hans R, Takkar A, Ahuja CK, Lamba DS, Lal V, et al. Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add-on therapy in acute attacks of neuromyelitis optica spectrum disorder. J Clin Apher. 2024;39(3):e22129.

38. Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler J. 2014;20(11):1533–40.

39. Levy M, Mealy MA. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2014;1(1):e5.

40. Lin J, Xue B, Zhu R, Pan J, Li J, Lin Y, et al. Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurol Sci. 2021;42(9):3857–63.

41. Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine Baltimore. 2019;98(25):e15944.

42. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197–200.

43. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59(3):566–9.

44. Masuda H, Mori M, Uzawa A, Muto M, Uchida T, Ohtani R, et al. Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. J Neurol Sci. 2016;367.

45. Papp V, Magyari M, Möller S, Sellebjerg F, Battistini JL, Svendsen KB, et al. Mortality of the Danish nationwide AQP4 antibody-seropositive neuromyelitis optica spectrum disorder patient cohort. Neurology. 2024;102(5):e209147.

46. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003;60(5):848–53.

47. Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2023;75(12):2088–102.

48. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007;13(8):968–74.

49. Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013;84(5):511–6.

50. Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84(8):918–21.

51. Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003–9.

52. Wang Y, Ma J, Chang H, Zhang X, Yin L. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta-analysis. Mult Scler Relat Disord. 2021;55:103181.

53. Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med. 2013;52(9):969–72.

54. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019–32.

55. Carnero Contentti E, Rojas JI, Cristiano E, Marques VD, Flores-Rivera J, Lana-Peixoto M, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord. 2020;45:102428.

56. Shosha E, Aljarallah SA, Al Fugham N, Al-Jedai AH, Al Luqmani MM, Al Malik YM, et al. Saudi consensus recommendations on the management of neuromyelitis optica spectrum disorders (NMOSD). Multiple Scler Relat Disord. 2022;66:104062.

57. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77(7):659–66.

58. Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised

recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024;271(1):141–76.

59. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324–30.

60. Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2018;385:192–7.

61. Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord. 2019;33:22–32.

62. Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391–401.

63. Chen H, Qiu W, Zhang Q, Wang J, Shi Z, Liu J, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol. 2017;24(1):219–26.

64. Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev. 2007;2007(4):Cd003982.

65. Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics. 2006;24(8):767–81.

66. San Martin DL, Fukuda TG, Nascimento TS, Silva MB, Filho MBP, Forcadela M, et al. Predictors of azathioprine and mycophenolate mofetil response in patients with neuromyelitis optica spectrum disorder: a cohort study. Mult Scler Relat Disord. 2024;83:105452.

67. Songwisit S, Kosiyakul P, Jitprapaikulsan J, Prayoonwiwat N, Ungprasert P, Siritho S. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep. 2020;7(1):16727.

68. Lin J, Xue B, Li J, Zhu R, Pan J, Chen Z, et al. Comparison of long-term use of low dose rituximab and mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorder. Front Neurol. 2022;13:891064.

69. Kylat RI. What is the teratogenic risk of mycophenolate? J Pediatr Genet. 2017;6(2):111–4.

70. Ng ASL, Tan K. Methotrexate is effective for the treatment of neuromyelitis optica spectrum disorders in Asian patients. Clinical and Experimental Neuroimmunology. 2015;6(2):149–53.

71. Ramanathan RS, Malhotra K, Scott T. Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol. 2014;14:51.

72. Kim S-H, Huh S-Y, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110–7.

73. Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of *FCGR3A* polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989–95.

74. Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised,

75. double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298–306.

75. Gao X, Wang Y, Xu Z, Deng H, Yang H, Zhong F. Systematic review and meta-analysis of rituximab for steroid-dependent or frequently relapsing nephrotic syndrome in children. Front Pediatr. 2021;9:626323.

76. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909–20.

77. Barreras P, Vasileiou ES, Filippatou AG, Fitzgerald KC, Levy M, Pardo CA, et al. Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology. 2022;99(22):e2504–16.

78. Kim SH, Park NY, Kim KH, Hyun JW, Kim HJ. Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience. Neurol Neuroimmunol Neuroinflamm. 2022. https://doi.org/10.1212/NXI.0000000000001179.

79. Rual C, Biotti D, Lepine Z, Delourme A, Berre JL, Treiner E, et al. 2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: What B-cell repopulation data tell us. Mult Scler Relat Disord. 2023;71:104563.

80. Nasir M, Hone L, Tallantyre E, Kelly P, Leite MI, Robertson N, et al. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2024;85:105528.

81. Hayes MTG, Adam RJ, McCombe PA, Walsh M, Blum S. Long-term efficacy and safety of rituximab in the treatment of neuromyelitis optica spectrum disorder. Mult Scler J. 2024;10(2):20552173241257876.

82. Zhang C, Liu R, Gao B, Li T, Wang H, Song T, et al. Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder. J Neuroimmunol. 2024;387:578285.

83. Zhao D, Ren K, Lu J, Liu Z, Li Z, Wu J, et al. Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study. Front Immunol. 2023;14:1148632.

84. Bruschi N, Malentacchi M, Malucchi S, Sperli F, Martire S, Sala A, et al. Tailoring rituximab according to CD27-positive B-cell versus CD19-positive B-cell monitoring in neuromyelitis optica spectrum disorder and MOG-associated disease: results from a single-center study. Neurol Ther. 2023;12(4):1375–83.

85. Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016;18(1):131.

86. Frampton JE. Inebilizumab: first approval. Drugs. 2020;80(12):1259–64.

87. Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, et al. International delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023. https://doi.org/10.1212/NXI.0000000000200124.

88. Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–63.

89. Flanagan EP, Levy M, Katz E, Cimbora D, Drappa J, Mealy MA, et al. Inebilizumab for treatment of neuromyelitis optica

spectrum disorder in patients with prior rituximab use from the N-MOmentum study. Mult Scler Relat Disord. 2022;57:103352.

90. Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, et al. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2022;57:103356.

91. Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ≥4 years in the N-MOmentum trial. Mult Scler. 2022;28(6):925–32.

92. FDA. Inebilizumab (UPLIZNA) Prescribing Information2020 04 Marc 2025. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf.

93. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–43.

94. Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13(4):e0195909.

95. Pittock SJ, Barnett M, Bennett JL, Berthele A, de Sèze J, Levy M, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93(6):1053–68.

96. Pittock S, Barnett M, Bennett J, Berthele A, de Sèze J, Levy M, et al. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial (S5.002). Neurology. 2023;100(17_supplement_2):2965.

97. Clardy SL, Pittock SJ, Aktas O, Nakahara J, Isobe N, Centonze D, et al. Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder. Neurol Ther. 2024;13(3):535–49.

98. Lee JW, de Sicre Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Füreder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–9.

99. CDC. Clinical guidance for managing meningococcal disease risk in patients receiving complement inhibitor therapy2024 18 Mar 2025. Available from: https://www.cdc.gov/meningococcal/hcp/clinical-guidance/complement-inhibitor.html.

100. Pittock SJ, Weitz I, Howard JF, Sabatella G, Mehta S, Franklin J. Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. CNS Spectr. 2021;26(3):195–6.

101. Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701–6.

102. Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4(1):e311.

103. Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;39:101920.

104. Heo YA. Satralizumab: first approval. Drugs. 2020;80(14):1477–82.

105. Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–24.

106. Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402–12.

107. Nakashima I, Nakahara J, Yasunaga H, Yamashita M, Nishijima N, Satomura A, et al. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database. Mult Scler Relat Disord. 2024;84:105502.

108. Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66:104025.

109. Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023;10(1).

110. Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party. Mult Scler. 2015;21(2):189–97.

111. Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019;93(18):e1732–41.

112. Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023;8(1):5.

113. Demuth S, Collongues N, Audoin B, Ayrignac X, Bourre B, Ciron J, et al. Rituximab de-escalation in patients with neuromyelitis optica spectrum disorder. Neurology. 2023;101(4):e438–50.

114. Kim SH, Jang H, Park NY, Kim Y, Kim SY, Lee MY, et al. Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. Neurol Neuroimmunol Neuroinflamm. 2021. https://doi.org/10.1212/NXI.0000000000000947.

115. Shosha E. Disease-modifying therapies should be stopped in NMOSD patients in remission - yes. Mult Scler. 2019;25(9):1217–8.

116. Pandit L, Mustafa S. Spontaneous remission lasting more than a decade in untreated AQP4 antibody-positive NMOSD. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e351.

117. Weinfurtner K, Graves J, Ness J, Krupp L, Milazzo M, Waubant E. Prolonged remission in neuromyelitis optica following cessation of rituximab treatment. J Child Neurol. 2015;30(10):1366–70.

118. Wu Y, Geraldes R, Juryńczyk M, Palace J. Double-negative neuromyelitis optica spectrum disorder. Mult Scler. 2023;29(11–12):1353–62.

119. Mealy MA, Kim SH, Schmidt F, López R, Jimenez Arango JA, Paul F, et al. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler. 2018;24(13):1737–42.

120. Yang Y, Chen L, Wu L, Yao J, Wang N, Su X, et al. Effective rituximab treatment in patients with neuromyelitis optica spectrum disorders compared with azathioprine and mycophenolate. Neurol Ther. 2022;11(1):137–49.

121. Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):756–63.

122. Rocchi C, Forcadela M, Kelly P, Linaker S, Gibbons E, Bhojak M, et al. The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis. Mult Scler. 2024;30(3):345–56.

123. Quek AM, McKeon A, Lennon VA, Mandrekar JN, Iorio R, Jiao Y, et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol. 2012;69(8):1039–43.

124. Pizzolato Umeton R, Waltz M, Aaen GS, Benson L, Gorman M, Goyal M, et al. Therapeutic response in pediatric neuromyelitis optica spectrum disorder. Neurology. 2023;100(9):e985–94.

125. Longoni G, Banwell B, Filippi M, Yeh EA. Rituximab as a first-line preventive treatment in pediatric NMOSDs: preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e46.

126. Nosadini M, Alper G, Riney CJ, Benson LA, Mohammad SS, Ramanathan S, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflammation. 2016;3(1):e188.

127. Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142–50.

128. Breu MGS, Hoftberger R, Freilinger M, Kircher K, Kasprian G, Seidl R, et al. Two cases of pediatric AQP4-antibody positive neuromyelitis optica spectrum disorder successfully treated with tocilizumab. Neuropediatrics. 2919;50:193–6.

129. Perera A, Chugh N, Garcia-Bournissen F. Systematic review of adverse events of IL-1 and IL-6 inhibitor use in pediatrics. J Pediatr Pharmacol Ther. 2025;30(2):152–69.

130. Enriquez M, Rosenthal S, McLendon LA, Bennett JL, Piquet AL, Kammeyer R. Efficacy of eculizumab in acute refractory pediatric neuromyelitis optica: a case report. Neuroimmunol Rep. 2024;5:100213.

131. Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701–11.

132. Tanaka K, Adams B, Aris AM, Fujita N, Ogawa M, Ortiz S, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021;36(4):889–98.

133. Yonekawa M, Nishioka M, Yazawa S, Yabe M, Murase T, Matsuoka D, et al. Delayed visual improvement in a pediatric patient with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder after acute immunomodulatory treatment: a case report. Brain Dev Case Rep. 2024;2(2):100012.

134. Paolilo RB, Hacohen Y, Yazbeck E, Armangue T, Bruijstens A, Lechner C, et al. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: a multinational pediatric study. Neurol Neuroimmunol Neuroinflamm. 2020. https://doi.org/10.1212/NXI.0000000000000837.

135. Li Z, Wan L, Liu X, Wang J, Shi X, Zhou H, et al. Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder. Front Immunol. 2022;13:1113406.

136. Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775–83.

137. Delgado-García G, Chávez Z, Rivas-Alonso V, Corona T, Flores-Rivera J. Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody-seropositive neuromyelitis optica. Mult Scler Relat Disord. 2018;25:268–70.

138. Gad AH, Kishk N, Shalaby NM, Heikal ES, Fouad AM, Merghany N, et al. Pregnancy characteristics in Egyptian female patients with NMOSD. Mult Scler J. 2024;10(3):20552173241271878.

139. Kim W, Kim SH, Nakashima I, Takai Y, Fujihara K, Leite MI, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78(16):1264–7.

140. Nour MM, Nakashima I, Coutinho E, Woodhall M, Sousa F, Revis J, et al. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology. 2016;86(1):79–87.

141. Saadoun S, Waters P, Leite MI, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol. 2013;191(6):2999–3005.

142. Siriratnam P, Huda S, Butzkueven H, van der Walt A, Jokubaitis V, Monif M. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: a comprehensive review. Autoimmun Rev. 2024;23(2):103499.

143. Shosha E, Pittock SJ, Flanagan E, Weinshenker BG. Neuromyelitis optica spectrum disorders and pregnancy: interactions and management. Mult Scler. 2017;23(14):1808–17.

144. Du Q, Shi Z, Chen H, Zhang Y, Qiu Y, Lang Y, et al. Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks. Ann Clin Transl Neurol. 2022;9(12):1918–25.

145. Ringelstein M, Harmel J, Distelmaier F, Ingwersen J, Menge T, Hellwig K, et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler. 2013;19(11):1544–7.

146. Fragoso YD, Adoni T, Bichuetti DB, Brooks JB, Ferreira ML, Oliveira EM, et al. Neuromyelitis optica and pregnancy. J Neurol. 2013;260(10):2614–9.

147. Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, et al. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017;89(22):2238–44.

148. Shimizu Y, Fujihara K, Ohashi T, Nakashima I, Yokoyama K, Ikeguch E, et al. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler. 2016;22(11):1413–20.

149. Tallavajhala V, Padarti A, Kilgo W. Neuromyelitis optica spectrum disorder relapse during the third trimester of pregnancy. Neuroimmunol Rep. 2022;2:100134.

150. Vukusic S, Marignier R, Ciron J, Bourre B, Cohen M, Deschamps R, et al. Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society. Mult Scler. 2023;29(1):37–51.

151. Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of women with multiple sclerosis planning pregnancy. Curr Treat Options Neurol. 2021;23(4):11.

152. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15–22.

153. Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810.

154. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149a(6):1241–8.

155. Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158a(3):588–96.

156. Klieger-Grossmann C, Chitayat D, Lavign S, Kao K, Garcia-Bournissen F, Quinn D, et al. Prenatal exposure to mycophenolate mofetil: an updated estimate. J Obstet Gynaecol Can. 2010;32(8):794–7.

157. Verberne EA, de Haan E, van Tintelen JP, Lindhout D, van Haelst MM. Fetal methotrexate syndrome: a systematic review of case reports. Reprod Toxicol. 2019;87:125–39.

158. DeSesso JM, Williams AL, Ahuja A, Bowman CJ, Hurtt ME. The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. Crit Rev Toxicol. 2012;42(3):185–210.

159. Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod. 1999;4(2):81–9.

160. Langer-Gould AM. Pregnancy and family planning in multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):773–92.

161. Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e453.

162. Kümpfel T, Thiel S, Meinl I, Ciplea AI, Bayas A, Hoffmann F, et al. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany. Neurol Neuroimmunol Neuroinflamm. 2021. https://doi.org/10.1212/NXI.0000000000000913.

163. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–506.

164. Leite MI, Panahloo Z, Harrison N, Palace J. A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD). Mult Scler Relat Disord. 2023;75:104760.

165. Leung E, Crass RL, Jorgensen SCJ, Raybardhan S, Langford BJ, Moore WJ, et al. Pharmacokinetic/pharmacodynamic considerations of alternate dosing strategies of tocilizumab in COVID-19. Clin Pharmacokinet. 2022;61(2):155–65.

166. Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, Guibert Sd, Röth A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032–9.

167. Bjørn AM, Ehrenstein V, Nohr EA, Nørgaard M. Use of inhaled and oral corticosteroids in pregnancy and the risk of malformations or miscarriage. Basic Clin Pharmacol Toxicol. 2015;116(4):308–14.

168. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):585.e1-7 (**discussion 683-4, e1-7**).

169. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796–804.

170. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–92.

171. Skuladottir H, Wilcox A, McConnaughey R, Vindenes H, Lie RT. First-trimester nonsystemic corticosteroid use and the risk of oral clefts in Norway. Ann Epidemiol. 2014;24(9):635–40.

172. Canibaño B, Deleu D, Mesraoua B, Melikyan G, Ibrahim F, Hanssens Y. Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. J Drug Assess. 2020;9(1):20–36.

173. Mao-Draayer Y, Thiel S, Mills EA, Chitnis T, Fabian M, Katz Sand I, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020;16(3):154–70.

174. Socié G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297–310.

Authors and Affiliations

Bassem Yamout[1] · Riadh Gouider[2] · Raed Al-Roughani[3] · Salman Aljarallah[4] · Nevine Shalaby[5] · Jaber Al-Khabouri[6] · Anu Jacob[7] · Jihad Inshasi[8,9] · Akram Mahdawi[10] · Ahmed Shatila[11] · Maya Zeineddine[12] · **Sarmad Al-Mashetah[10] · Beatrice Canibano[13,14] · Saeed Bohlega[15] · Fatema Abdulla[16] · Ilham Slassi[17] · Aly Hassan[18] · Sandra Ahmed[19] · Magd Zakaria[20] · Mohammed AlJumah[21] · Yaser Al-Malik[22,23,24]**

✉ Maya Zeineddine
mzeineddine39@gmail.com; maya.zeineddine@lau.edu.lb

1   Neurology Institute, Harley Street Medical Centre, Abu Dhabi, United Arab Emirates

2   Department of Neurology, LR18SP03, Clinical Investigation Center "Neurosciences and Mental Health"-Razi University Hospital-Mannouba, Tunis, Tunisia

3   Amiri Hospital, Kuwait, Kuwait

4   College of Medicine, King Saud University, Riyadh, Saudi Arabia

5   Neurology Department, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt

6   Department of Neurology, The Royal Hospital, Muscat, Oman

7   Neurology Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates

8   Neuroscience Department, Rashid Hospital, Dubai, United Arab Emirates

9   Dubai Medical College, Dubai, United Arab Emirates

10 Baghdad Teaching Hospital, Medical City Complex, Baghdad, Iraq

11 Neurology Department, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates

12 School of Pharmacy, Lebanese American University, Byblos, Lebanon

[13] Neuroscience Institute, Hamad Medical Corporation, Doha, Qatar

[14] Neuroscience Institute, Weill-Cornell Medicine Qatar (WCMQ), Al-Rayyan, Qatar

[15] King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

[16] Salmaniya Medical Complex, Government Hospitals, Manama, Kingdom of Bahrain

[17] Hôpital Cheikh Khalifa Ibn Zaid, Casablanca, Morocco

[18] Department of Neurology, Tawam Hospital, Al-Ain, United Arab Emirates

[19] Department of Neurology, Multiple Sclerosis Clinic, Kasr Al-Ainy Hospital, Cairo University, Giza, Egypt

[20] Ain Shams University, Cairo, Egypt

[21] King Fahad Medical City, Ministry of Health, Riyadh, Saudi Arabia

[22] College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

[23] King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

[24] Department of Neurology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia